We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
GLOBETECH PUBLISHING LLC

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

Novel Presepsin Assay Evaluated Using Automated Immunoanalyzer

By LabMedica International staff writers
Posted on 27 Jul 2022
Print article
Image: The HISCL Presepsin Assay Kit can be used with its Automated Immunoassay System HISCL-5000/2000i/800 for immunochemistry testing (Photo courtesy of Sysmex Corporation)
Image: The HISCL Presepsin Assay Kit can be used with its Automated Immunoassay System HISCL-5000/2000i/800 for immunochemistry testing (Photo courtesy of Sysmex Corporation)

Biomarkers that reflect systemic responses during sepsis have been studied continuously, and there are various surrogate markers for the diagnosis of sepsis. Procalcitonin (PCT), C-reactive protein (CRP), cytokines, and chemokines have been studied extensively under the previous and revised sepsis definitions.

A soluble CD14 molecule (presepsin) has been developed and applied toward the diagnosis and prognosis of sepsis. Presepsin is a soluble CD14 molecule that is cleaved and released into the general circulation after activation by a monocyte or macrophage. Pathogen-associated molecular species such as lipopolysaccharide (LPS) from gram-negative bacteria can bind to serum lipoprotein-binding protein, both of which bind to CD14.

Biomedical Scientists at the Seoul St. Mary's Hospital, College of Medicine (Seoul, South Korea) collected samples from sepsis patients visiting the emergency department were collected before a treatment. Sepsis was diagnosed using a SOFA score with suspected bacterial infection. Reference intervals were analyzed and 124 subjects without underlying disease or prescribed medication from electronic medical records were selected.

For method comparison, 87 samples from suspected sepsis patients were collected within 24 hours from blood drawn and refrigerated at −80 °C for method comparison in duplicate. A total of 84 plasma from EDTA samples was analyzed with the chemiluminescence enzyme immunoassay by both Sysmex HISCL-5000 (Sysmex Corporation, Kobe, Japan) and PATHFAST (LSI Medience Corporation, Tokyo, Japan). For Sysmex HISCL-5000, the measurement range was from 0 to 30,000 pg/mL and for PATHFAST, the measurement range was from 0 to 20,000 pg/mL. Precision, linearity, limit of blank/limit of detection, method comparisons, and reference intervals were evaluated.

The investigators reported that precision using a 20×2×2 protocol for low (306 pg/mL) and high (1,031 pg/mL) levels resulted in within-laboratory standard deviation (95% confidence interval [CI]) and coefficient of variation (CV) %, which were as follows: 15.3 (13.1–18.7), 5.5% and 47.7, (40.5–58.1), 6.4%, respectively. Linearity using patient samples and calibrators were measured from 201 to 16,177 and 188 to 30,000 pg/mL, respectively. The correlation coefficient (95% CI) was 0.869 (0.772–0.927) with statistical significance. Reference intervals from 120 normal healthy subjects showed that 300 pg/mL was the cut off. Presepsin tended to show a higher value at higher ages and in males. A method comparison between Sysmex HISCL-5000 and PATHFAST was performed and the correlation coefficient was 0.979, which showed a high correlation coefficient.

The authors concluded that presepsin analyzed by HISCL-5000 showed reliable analytical performance that could be used in clinical settings. A wide range of analytical measurements ranging from 200 to 30,000 pg/mL was verified. As presepsin showed positive and negative correlations with hematocrit and renal function, careful interpretation is required for patients with underlying diseases involving red blood cells or kidneys. The study was published on July 23 2022 in the Journal of Clinical Laboratory Analysis.

Related Links:
Seoul St. Mary's Hospital, College of Medicine 
Sysmex Corporation 
LSI Medience Corporation 

Gold Supplier
ESR Analyzer
miniiSED™
New
Microtome
M-250
New
Electronic Pipette
Eppendorf Xplorer/ Eppendorf Xplorer plus
New
Silver Supplier
Urinalysis Dipstick Control
Dipper Urinalysis Dipstick Control

Print article
SUGENTECH INC.

Channels

Microbiology

view channel
Image: Ring-form trophozoites of Plasmodium vivax in a thin blood smear (Photo courtesy of Centers for Disease Control and Prevention)

Immune Regulators Predict Severity of Plasmodium vivax Malaria

Cytokines and chemokines are immune response molecules that display diverse functions, such as inflammation and immune regulation. In Plasmodium vivax infections, the uncontrolled production of these molecules... Read more

Pathology

view channel
Image: Breast cancer spread uncovered by new molecular microscopy (Photo courtesy of Wellcome Sanger Institute)

New Molecular Microscopy Tool Uncovers Breast Cancer Spread

Breast cancer commonly starts when cells start to grow uncontrollably, often due to mutations in the cells. Overtime the tumor becomes a patchwork of cells, called cancer clones, each with different mutations.... Read more

Industry

view channel
Image: With Cell IDx’s acquisition, Leica Biosystems will be moving its multiplexing menu forward (Photo courtesy of Leica Biosystems)

Leica Biosystems Acquires Cell IDx, Expanding Offerings in Multiplexed Tissue Profiling

Leica Biosystems, a technology leader in automated staining and brightfield and fluorescent imaging (Nussloch, Germany), has acquired Cell IDx, Inc. (San Diego, CA, USA), which provides multiplex staining... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.